NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer

OBJECTIVES: NY-ESO-1 is a cancer testis antigen and a promising target for immunotherapy. The purpose of this study was to determine the expression frequency, immunogenicity, and clinical impact of NY-ESO-1 in ovarian cancer. METHODS: Immunohistochemistry (IHC), reverse-transcription polymerase chai...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gynecol Oncol
Autors principals: Szender, J. Brian, Papanicolau-Sengos, Antonios, Eng, Kevin H., Miliotto, Anthony J., Lugade, Amit A., Gnjatic, Sacha, Matsuzaki, Junko, Morrison, Carl D., Odunsi, Kunle
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5497581/
https://ncbi.nlm.nih.gov/pubmed/28392127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2017.03.509
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars